2Hart RG,Benavente O,McBride R,et al.Antithrombotic therapy to prevent stroke in patients with atrial fibrillation:a rmeta-analysis.Ann Intern Med,1999,131:492-501.
3Hirsh J,Fuster V,Ansell J,et al.American Heart Association/American College of Cardiology Foundation guide to warfarin therapy.J Am Coll Cardiol,2003,41:1633-1652.
4Hylek EM,Skates S J,Sheehan MA,et al.An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation.N Engl J Med,1996,335:540-546.
5Gullov AL,Koefoed BG,Petersen P,et al.Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation:Second Copenhagen Atrial Fibrillation,Aspirin,and Anticoagulation Study.Arch Intern Med,1998,158:1513-1521.
6Bleeding during antithrombotic therapy in patients with atrial fibrillation.The Stroke Prevention in Atrial Fibrillation Investigators.Arch Intern Med,1996,156:409-416.
7Hylek EM,Singer DE.Risk factors for intracranial hemorrhage in outpatients taking warfarin.Ann Intern Med,1994,120:897-902.
8Feinberg WM,Blackshear JL,Laupacis A,et al.Prevalence,age distribution,and gender of patients with atrial fibrillation.Analysis and implications.Arch Intern Med,1995,155:469-473.
9Murray RD,Deitcher SR,Shah A,et al.Potential clinical efficacy and cost benefit of a transesophageal echocardiography-guided lowmolecular-weight heparin (enoxaparin) approach to antithrombotic therapy in patients undergoing immediate cardioversion from atrial fibrillation.J Am Soc Echocardiogr,2001,14:200-208.
10Saoudi N,Schoels W,EL-Sherif N,eds.Atrial flutter and fibrillation:from basic to clinical applications[]..1998
10Joffe HV, Goldhaber SZ. Effectiveness and safety of long-term anticoagulation of patients ≥ 90 years of age with atrial fibrillation [J]. Am J Cardiol, 2002, 90 (12) : 1397-1398.
